Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
244 Results for "
Splicing
" in MedChemExpress (MCE) Product Catalog:
Products (244)
244 Results for "Splicing" in MCE Product Catalog:
Cat. No.: HY-182891
Target:
Research Areas:
MC4455 is a LSD1/PRMT5 dual inhibitor. MC4455 inhibits the LSD1/CoREST and PRMT5/MEP50 complex with IC50 values of 0.104 μM and 0.014 μM. MC4455 covalently binds to LSD1’s FAD cofactor, stabilizes the LSD1/CoREST complex. MC4455 induces myeloid differentiation, alters transcriptomic profiles, drives alternative splicing changes, and impairs leukemic cell viability in AML cells. MC4455 can be used for the research of acute myeloid leukemia .
Cat. No.: HY-21286
CAS No.: 63264-29-9
Target:
Research Areas:
N2-Isobutyryl-2'-O-methylguanosine is a nucleic acid synthesis intermediate (e.g., used in antisense oligonucleotides, mRNA modification), for example, it is a key monomer for the synthesis of 2'-O-methyl oligoribonucleotides. N2-Isobutyryl-2'-O-methylguanosine enables the final product to form stable double strands with complementary RNA and is not easily degraded by nucleases. N2-Isobutyryl-2'-O-methylguanosine is mainly used in molecular biology research, and can be used to prepare RNA hybridization probes or participate in related biochemical research such as pre-mRNA splicing mechanisms .
Cat. No.: HY-P1221
CAS No.: 484598-36-9
Target:
Research Areas:
Cat. No.: HY-15724AR
CAS No.: 886214-18-2
Synonyms: GSK-1605786 sodium (Standard); CCX282-B sodium (Standard); Traficet-EN sodium (Standard)
Target:
Research Areas:
Vercirnon (sodium) (Standard) is the analytical standard of Vercirnon (sodium). This product is intended for research and analytical applications. Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .
Cat. No.: HY-15724R
CAS No.: 698394-73-9
Synonyms: GSK-1605786 (Standard); CCX282-B (Standard); Traficet-EN (Standard)
Target:
Research Areas:
Vercirnon (Standard) is the analytical standard of Vercirnon. This product is intended for research and analytical applications. Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively .
Cat. No.: HY-173274
CAS No.: 3056259-55-0
Target:
Research Areas:
CB039 is a RBM39 molecular glue degrader with an IC50 of 36.7 nM against HCT-116 cells. CB039 induces RBM39 degradation in a dose- and time-dependent manner. This process depends on the Cullin-RING E3 ubiquitin ligase complex (CRL) and proteasome, and promotes the recruitment of RBM39 to the DCAF15-DDB1 complex with an IC50 of 594 nM. CB039 causes abnormal RNA splicing, reduces CEP192 protein levels, induces G2/M phase cell cycle arrest and mitotic spindle disorder. CB039 can be used in studies on RBM39-targeted protein degradation and colorectal cancer-related mechanisms .
Cat. No.: HY-174215
CAS No.: 3063511-09-8
Target:
Research Areas:
TAU-IN-3 (Compound 2) is an orally active TAU inhibitor. TAU-IN-3 inhibits the expression of MAPT exon 10 DDPAC mutant gene in HeLa cells (IC50: 0.6 µM). TAU-IN-3 reduces the 4R/3R MAPT mRNA ratio in HeLa cells transfected with WT or DDPAC minigenes. TAU-IN-3 inhibits the insertion of endogenous MAPT exon 10 and the production of 4R tau protein in cells. TAU-IN-3 modulates tau splicing in htau mice and improves the associated behavioral phenotypes. TAU-IN-3 can be used to study neurodegenerative diseases .
Cat. No.: HY-403733B
CAS No.: 1998094-24-8
Research Areas:
(+)-JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR) that inhibits AR nuclear localization and transcriptional activity in the absence of androgen. (+)-JJ-450 is less active than (-)-JJ-450 (HY-403733A) in inhibiting prostate-specific antigen (PSA) expression in LN95 cells, possibly because (+)-JJ-450 targets the ligand binding domain (LBD) of AR. (+)-JJ-450 inhibits the transcriptional activity of AR and its splice variants (e.g., ARv7) by promoting the degradation of unliganded AR in the nucleus and reducing the binding of AR to androgen response elements (AREs). (+)-JJ-450 can be used in castration-resistant prostate cancer (CRPC) studies that are resistant to enzalutamide (MDV3100) (HY-70003) .
Cat. No.: HY-403733C
CAS No.: 2020353-42-6
Target:
Research Areas:
JJ-450 is a non-competitive antagonist androgen receptor (AR) that inhibits the transcriptional activity of wild-type AR and mutant AR F876L. JJ-450 has an IC50 of approximately 1-10 μM in inhibiting AR transcriptional activity in PC3 cells. It is selective for AR binding and does not compete with androgens for binding to the ligand binding domain (LBD) of AR. JJ-450 inhibits the transcriptional activity of AR and its splice variants (such as AR F876L) by inhibiting AR nuclear translocation and promoting the degradation of unliganded AR in the nucleus. JJ-450 can be used in castration-resistant prostate cancer (CRPC) studies that are resistant to Enzalutamide (MDV3100) (HY-70003) .
Cat. No.: HY-P1221A
Target:
Research Areas:
Cat. No.: HY-W1058476
CAS No.: 1443367-20-1
Research Areas:
GPR35 agonist 6 is a potent and selective agonist targeting GPR35, with an EC50 of 12.1 nM against human GPR35. GPR35 agonist 6 activates the human splice variant GPR35b with comparable efficacy, showing an EC50 of 22.1 nM. GPR35 agonist 6 also exhibits weak GPR55 antagonistic activity, with an IC50 of 21.7 μM, and its agonistic activity towards GPR35 is significantly stronger than its antagonistic activity towards GPR55. GPR35 agonist 6 initiates GPR35 downstream signaling by inducing β-arrestin recruitment. GPR35 agonist 6 is used to investigate GPR35-mediated diseases, such as gastrointestinal lesions and gastric cancer .
Cat. No.: HY-145725A
CAS No.: 1698048-23-5
Synonyms: ISIS 598769; IONIS 598769; BIIB 065; ISIS-DMPK-2.5Rx
Target:
Research Areas:
Baliforsen (ISIS 5987690) is an antisense oligonucleotide (ASO) that inhibits DMPK mRNA. Baliforsen binds within exon 9 of the human DMPK transcript to promote RNase H1-mediated degradation Baliforsen can be used for the research of myotonic dystrophy type 1 .
Cat. No.: HY-P705802
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDK5; Cyclin-Dependent Kinase 5; Cyclin Dependent Kinase 5; TPKII Catalytic Subunit; PSSALRE; Epididymis Secretory Sperm Binding Protein; Serine/Threonine-Protein Kinase PSSALRE; Protein Kinase CDK5 Splicing; Tau Protein Kinase II Catalytic Subunit; CDKN5
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-170935
SRSF1-IN-1 is a SRSF1 inhibitor. SRSF1-IN-1 inhibits SRSF1 expression, thereby modulating the splicing of Bcl-x pre-mRNA. SRSF1-IN-1 inhibits the proliferation of various cancer cells. SRSF1-IN-1 induces apoptosis in gastric cancer cells, reduces Bcl-xl expression, and upregulates cleaved PARP and caspase 3. SRSF1-IN-1 induces autophagy and promotes cell death. SRSF1-IN-1 exhibits anti-tumor activity in a mouse gastric cancer xenograft model. SRSF1-IN-1 can be used for the research of various cancers including liver cancer, gastric cancer, breast cancer, colon cancer, glioma, and melanoma .
Cat. No.: HY-187172
CAS No.: 2060801-74-1
Target:
Research Areas:
BDF34019555 is a blood-brain barrier-permeable binder targeting the conserved region (amino acid residues 320-340) of TDP-43, with a Kd of 10.4 μM for full-length TDP-43 and 7.8 μM for the CR polypeptide, respectively. BDF34019555 binds to the conserved α-helical region of TDP-43 in a Trp334-dependent manner, inhibits liquid-liquid phase separation, aggregation and mitochondrial localization of TDP-43, restores mitochondrial function, reduces cytoplasmic and insoluble TDP-43 levels, without affecting the splicing activity of TDP-43. BDF34019555 exerts neuroprotective effects, alleviates motor neuron loss and improves motor neuron function. BDF34019555 can be used in studies related to amyotrophic lateral sclerosis .
Cat. No.: HY-187810
Synonyms: LC-04-118
Research Areas:
dWBP4-1 (LC-04-118) is a CRBN-dependent molecular glue degrader targeting WBP4. dWBP4-1 binds to the IMiD site of CRBN via its glutarimide ring, induces the formation of the CRBN-WBP4 ternary complex (EC50 = 224 nM), and mediates the rapid degradation of WBP4 through the G-loop dependent ubiquitin-proteasome pathway, a process that can be rescued by MLN4924 (HY-70062), Lenalidomide (HY-A0003) or Bortezomib (HY-10227). dWBP4-1 causes almost no perturbation at the transcriptome and alternative splicing levels, exhibits no obvious cytotoxicity, and produces no hook effect. dWBP4-1 can be used for the construction of chemical genetic protein degradation platforms and research related to acute T-lymphoblastic leukemia .
Cat. No.: HY-P7649
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: BCAS2; Breast Carcinoma Amplified Sequence 2; BCAS2 Pre-MRNA Processing Factor; Spliceosome-Associated Protein SPF 27; DAM1; Spliceosome Associated Protein, Amplified In Breast Cancer; Pre-MRNA-Splicing Factor SPF27; Breast Carcinoma-Amplified Sequence 2
Species:
Human
Source:
E. coli
Cat. No.: HY-P700271
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: BCAS2; Breast Carcinoma Amplified Sequence 2; BCAS2 Pre-MRNA Processing Factor; Spliceosome-Associated Protein SPF 27; DAM1; Spliceosome Associated Protein, Amplified In Breast Cancer; Pre-MRNA-Splicing Factor SPF27; Breast Carcinoma-Amplified Sequence 2
Species:
Human
Source:
E. coli
Cat. No.: HY-P702685
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDK5; Cyclin-Dependent Kinase 5; Cyclin Dependent Kinase 5; TPKII Catalytic Subunit; PSSALRE; Epididymis Secretory Sperm Binding Protein; Serine/Threonine-Protein Kinase PSSALRE; Protein Kinase CDK5 Splicing; Tau Protein Kinase II Catalytic Subunit; CDKN5
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P702686
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: CDK5; Cyclin-Dependent Kinase 5; Cyclin Dependent Kinase 5; TPKII Catalytic Subunit; PSSALRE; Epididymis Secretory Sperm Binding Protein; Serine/Threonine-Protein Kinase PSSALRE; Protein Kinase CDK5 Splicing; Tau Protein Kinase II Catalytic Subunit; CDKN5
Species:
Human
Source:
Sf9 insect cells
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
